表紙
市場調查報告書

關注市場分析:惡病質

Market Spotlight: Cachexia

出版商 Datamonitor Healthcare 商品編碼 923384
出版日期 內容資訊 英文 26 Pages
商品交期: 最快1-2個工作天內
價格
關注市場分析:惡病質 Market Spotlight: Cachexia
出版日期: 2020年07月22日內容資訊: 英文 26 Pages
簡介

惡病質的臨床開發的治療,以Ghrelin受體,雄激素受體,及GDNF受體Alpha樣等標的為焦點。這些藥物,是口服及由皮下途徑投藥。

本報告提供全球惡病質的市場調查,疾病的背景、概要,開發平台藥物及已上市藥物概要,臨床試驗狀況,今後的法規,成功概率,專利資訊,授權、資產收購等的主要交易趨勢,主要藥物的收益預測等彙整資料。

概要

要點

疾病的背景

  • 疾病定義
  • 患者的區分
  • 症狀
  • 風險群組
  • 診斷方法

治療

  • 治療策略
  • 藥物類別

流行病學

  • 癌症惡病質的盛行率
  • 其他主因素的惡病質的盛行率

已上市藥物

開發平台藥物

近幾年的活動

成功確立

授權、資產收購契約

本源專利

商機

臨床試驗環境

文獻

附錄

目錄
Product Code: DMKC0211594

This Market Spotlight report covers the Cachexia market, comprising epidemiology, key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals.

Key Takeaways

Oxandrin, an orally active formulation of the anabolic steroid oxandrolone, is the only marketed drug available for cachexia. Industry-sponsored drugs in active clinical development for cachexia are spread evenly across Phase I and Phase II, with only one drug in Phase III.

Therapies in active clinical development for cachexia focus on targets such as ghrelin receptor, androgen receptors, and GDNF receptor alpha-like (GFRAL). These drugs are administered via the oral and subcutaneous routes.

The only high-impact upcoming event for drugs in the cachexia space is topline Phase II trial results for GSK2881078. The overall likelihood of approval of a Phase I metabolic-other asset is 10.2%, and the average probability a drug advances from Phase III is 70.6%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.0 years in the overall metabolic space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for cachexia have been in the early and midphases of development, with 66% of trials in Phase I-II, and only 34% in Phase III-IV.

The US has a substantial lead in the number of cachexia clinical trials globally, while the UK leads the major European markets. Clinical trial activity in the cachexia space is dominated by completed trials. Helsinn and Bristol Myers Squibb have the highest number of completed clinical trials for cachexia, with six trials each.

Helsinn leads industry sponsors with the highest overall number of clinical trials for cachexia, followed by Bristol Myers Squibb and GlaxoSmithKline.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk groups
  • Diagnosis

TREATMENT

  • Treatment strategy
  • Drug classes

EPIDEMIOLOGY

  • Cancer cachexia prevalence
  • Prevalence of cachexia due to other main causes

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for cachexia in the US
  • Figure 2: Pipeline drugs for cachexia, by company
  • Figure 3: Pipeline drugs for cachexia, by drug type
  • Figure 4: Pipeline drugs for cachexia, by classification
  • Figure 5: Key upcoming events in cachexia
  • Figure 6: Probability of success in the cachexia pipeline
  • Figure 7: Clinical trials in cachexia
  • Figure 8: Top 10 drugs for clinical trials in cachexia
  • Figure 9: Top 10 companies for clinical trials in cachexia
  • Figure 10: Trial locations in cachexia
  • Figure 11: Cachexia trials status
  • Figure 12: Cachexia trials sponsors, by phase

LIST OF TABLES

  • Table 1: Drugs used for the treatment of cachexia
  • Table 2: Marketed drugs for cachexia
  • Table 3: Pipeline drugs for cachexia in the US